Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Qihan Raises $67 Million for Gene Editing of Cell Therapies, Organ Transplant Drugs

publication date: Mar 29, 2021

Qihan Biotechnology, a Hangzhou gene editing company, raised $67 million in a Series A++ round to advance its portfolio of novel autologous cell therapies. The company uses its multiplexable genome editing technology to develop cell therapies and facilitate organ transplants. With the new capital, Qihan plans to conduct IND-enabling studies and hypoimmunity projects, plus expand its manufacturing facility. The round was backed by Lilly Asia Ventures, Matrix Partners China, Sequoia and CMB International. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital